Personalis, Inc. Releases the Latest Version of NeoantigenID™ for Enhanced Neoantigen Identification on the ACE ImmunoID™ Platform

Menlo Park, CA — February 8, 2018 — Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced the latest release of NeoantigenID™, a component of the ACE ImmunoID™ Platform. ACE ImmunoID, which uses Personalis’ patented ACE Technology™, combines augmented exome and transcriptome sequencing with analytics to enable broad tumor immunogenomic characterization.

This newest release of NeoantigenID not only identifies candidate neoantigens derived from single nucleotide variants (SNVs), but now also includes putative neoantigens derived from insertion and deletion mutations (indels) and gene fusions, for both MHC Class I and Class II. The new analytics integrate DNA and RNA sequencing data to calculate neoantigen load, expression of genes, and expression of variants, while incorporating phasing information to improve the accuracy of neoantigen prediction.

“NeoantigenID allows our partners to develop personalized immunotherapies for each patient that target neoantigens unique to each patient’s tumor,” said Personalis, CSO, Dr. Richard Chen. “NeoantigenID is part of our broader ACE ImmunoID Platform where we aim to provide a comprehensive tumor immunogenomics solution that can enable personalized immunotherapies and biomarker identification for immuno-oncology.”

The company is presenting its complete suite of immunogenomics applications at this week’s Immuno-Oncology 360° Conference from Feb 7-9, 2018 in New York City.  Dr. Erin Newburn is presenting a talk entitled “Elucidating Neoantigens and Tumor Immunogenomics: Key Challenges and Solutions.” Representatives are in attendance to answer questions about the company’s immunogenomics and neoantigen identification capabilities.

About ACE™ Technology

Next-generation sequencing is increasingly used to support immuno-oncology studies. However, typical NGS cancer offerings fall short for immuno-oncology in a number of areas including gaps in gene coverage, narrow gene footprint, limited validation studies, and a lack of integrated RNA analysis. Personalis addresses these issues with proprietary Accuracy and Content Enhanced (ACE) technology which forms the foundation of ACE ImmunoID.

ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction, to library preparation and sequencing, to data analytics. This makes it possible to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques.

About Personalis

Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com

650-752-1300

2018-02-08T05:29:49+00:00